Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;18(2):397-407.
doi: 10.1007/s11739-022-03177-5. Epub 2022 Dec 20.

Serological response to COVID-19 pneumonia and increasing severity over 18 months in a prospective cohort of hospitalized patients

Collaborators, Affiliations

Serological response to COVID-19 pneumonia and increasing severity over 18 months in a prospective cohort of hospitalized patients

Gemma Grau Gómez et al. Intern Emerg Med. 2023 Mar.

Abstract

In this study, we present an 18-month serological follow-up of 294 patients with COVID-19 pneumonia. The aim was to assess the dynamics of serological response and its correlation with clinical worsening, as well as to describe clinical worsening determinants. Results of the study showed an early immunoglobulin M response, which clearly diminished starting at 4 months, but nonetheless, a small group of patients remained positive. As for immunoglobulin G, levels were higher up to 6 months in patients who presented clinical worsening during hospitalization. High titers of the immunoglobulin were maintained in all patients during follow-up, which would indicate that humoral immunity due to infection is long-lasting. Male sex, presence of myalgias and extensive radiological affectation were significantly correlated with clinical worsening.

Keywords: COVID-19 pneumonia; Clinical worsening; SARS-COV-2; Serological response.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no competing interests.

Figures

Fig. 1
Fig. 1
IgM and IgG prevalence over time since PCR diagnosis in the study cohort. *Evaluated between 5.1 and 7.8 months (mean: 6.5 months ± 0.39); ł evaluated between 9 and 11 months (mean: 9.9 ± 0.27); ≈ evaluated between 13 and 15 months (mean 14.3 ± 0.47)
Fig. 2
Fig. 2
IgM and IgG prevalence over time since symptoms onset in the study cohort. *Evaluated between 5.1 and 7.8 months (mean: 6.5 months ± 0.39); ł evaluated between 9 and 11 months (mean: 10.1 ± 0.33); ≈evaluated between 13 and 15 months (mean 14.6 ± 0.49)
Fig. 3
Fig. 3
Quantitative IgG values expressed as UA/mL over time in the study cohort
Fig. 4
Fig. 4
a (left) Absolute IgG values according to clinical worsening (no/yes) since diagnosis of SARS-CoV-2 infection by RT-PCR. b (right) Logarithm of IgG response according to clinical worsening (no/yes) since diagnosis of SARS-CoV-2 infection by RT-PCR
Fig. 5
Fig. 5
IgM prevalence with regard to clinical worsening during hospitalization. *Evaluated between 5.1 and 7.8 months (mean: 6.5 months ± 0.39); ł evaluated between 9 and 11 months (mean: 9.9 ± 0.27); ≈ evaluated between 13 and 15 months (mean 14.3 ± 0.47)

References

    1. Louie JK, Hacker JK, Mark J, et al. SARS and common viral infections. Emerging Infect Dis. 2004;10:1143–1146. doi: 10.3201/eid1006.030863. - DOI - PMC - PubMed
    1. Peeling RW, Heymann DL, Teo YY, et al. Diagnostics for COVID-19: moving from pandemic response to control. Lancet. 2022;399:757–768. doi: 10.1016/S0140-6736(21)02346-1. - DOI - PMC - PubMed
    1. Fang Y, Zhang H, Xie J, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology. 2020;296:115–117. doi: 10.1148/radiol.2020200432. - DOI - PMC - PubMed
    1. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020;296:32–40. doi: 10.1148/radiol.2020200642. - DOI - PMC - PubMed
    1. Burrell CJ, Howard CR, Murphy FA. Laboratory diagnosis of virus diseases. Fenner and White’s Med Virol. 2017;1:135–154. doi: 10.1016/B978-0-12-375156-0.00010-2. - DOI

Substances